Test for determining pyrogenic effect of a material

• US 5,891,728 A
• Filed: 05/02/1996
• Issued: 04/06/1999
• Est. Priority Date: 05/03/1995
• Status: Expired due to Term

• Current Assignee: Albrecht Wendel, Thomas Hartung
• Original Assignee: Albrecht Wendel, DPC Biermann GmbH, Thomas Hartung
• Inventors: Hartung, Thomas, Wendel, Albrecht
• Primary Examiner(s): WALLENHORST, MAUREEN
• Application Number:
  US08/643,126
• Time in Patent Office: 1,069 Days
• Field of Search: 436/2, 436/18, 436/63, 436/86, 435/2, 530/351
• US Class Current: 436/2
• CPC Class Codes: G01N 2400/50 Lipopolysaccharides; LPS
• CPC Class Codes: G01N 33/5047 Cells of the immune system

Abstract

A method of ascertaining the pyrogenicity of a material involves exposing to the material a sample of whole blood from a human or an amimal, followed by determining whether the exposure induces formation of endogenous pyrogen in the sample.

Claims

1. A method for evaluating safety or possible contamination of a product for use with humans or animals, by a pyrogen test comprising the steps of:

exposing a product intended for use with humans or animals to whole blood of a human in vitro or an animal in vitro;

followed by

subjecting a sample of the whole blood to an assay to determine whether the exposure induces formation of endogenous pyrogen in the sample;

whereby, the formation of endogenous pyrogen indicates the presence of an exogenous fever inducing agent in said product.

2. The method of claim 1 wherein the product has an unknown exogenous pyrogenic effect, the exposing step is performed in vitro on the sample of the whole blood, and the assay determines whether the product induces formation of endogenous pyrogen in the sample.

3. The method of claim 1 wherein the sample of whole blood includes components that prevent or retard blood clotting.

4. The method of claim 3 wherein the sample of whole blood includes a diluent.

5. The method of claim 4 wherein the diluent is cell-culture medium, physiological sodium chloride solution, or a mixture thereof.

6. The method of claim 3 wherein the endogenous pyrogen is interleukin-1.

7. The method of claim 3 wherein the endogenous pyrogen is interleukin-6.

8. The method of claim 3 wherein the endogenous pyrogen is tumor necrosis factor.

9. The method of claim 3 wherein the endogenous pyrogen is prostaglandin E₂.

10. The method of claim 1 wherein the sample of whole blood includes a diluent.

11. The method of claim 10 wherein the diluent is cell-culture medium, physiological sodium chloride solution, or a mixture thereof.

12. The method of claim 10 wherein the endogenous pyrogen is interleukin-1. interleukin-6, tumor necrosis factor, or prostaglandin E₂.

13. The method of claim 1 wherein the endogenous pyrogen is interleukin-1.

14. The method of claim 1 wherein the endogenous pyrogen is interleukin-6.

15. The method of claim 1 wherein the endogenous pyrogen is tumor necrosis factor.

16. The method of claim 1 wherein the endogenous pyrogen is prostaglandin E₂.

17. The method of claim 1 wherein the product is a medicinal drug.

18. The method of claim 17 wherein the medicinal drug is injectable or infusible.

19. The method of claim 1 wherein the product is a medical device.

20. The method of claim 1 wherein the product is a cosmetic.